AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023 Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today…
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30…
Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune…
A suit of armor for cancer-fighting cells In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process…
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets…
Turmeric may be as good for treating indigestion as drug to curb excess stomach acid A natural compound found in the culinary spice turmeric may be as effective as omeprazole – a drug used to curb excess stomach acid—for treating…
A free online tool can help prostate cancer patients save on out-of-pocket drug costs A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds. For patients enrolled in…
First-in-class targeted microRNA therapy slows cancer tumor growth A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated…
Why breast cancer survivors don’t take their medication, and what can be done For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they…
Cancer-infecting virus ‘warms up’ cold tumors and improves immunotherapy Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, according to a new study in…
Learning how to control HIV from African genomes Despite significant advances in treatment and access to therapy, the human immunodeficiency virus remains a global health challenge with almost 40 million affected individuals, no vaccine and no cure. The virus attacks…
